- Home
- ALIS vs ACRV Comparison
ALIS vs ACRV Comparison
Compare ALIS & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALIS | ACRV |
|---|---|---|
| Founded | 2024 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.9M | 74.0M |
| IPO Year | 2024 | 2022 |
Fundamental Metrics
Financial Performance| Metric | ALIS | ACRV |
|---|---|---|
| Price | $8.51 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 25.3K | ★ 216.5K |
| Earning Date | 01-01-0001 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 15.13 |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $204.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.70 | $1.27 |
| 52 Week High | $14.91 | $3.56 |
Technical Indicators
Market Signals| Indicator | ALIS | ACRV |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 40.97 |
| Support Level | $7.70 | $1.63 |
| Resistance Level | $10.17 | $2.21 |
| Average True Range (ATR) | 1.41 | 0.11 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 17.39 | 20.45 |
Price Performance
Historical ComparisonAbout ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.